Icon

ABILIFY (nda021436)- (2MG,5MG,10MG,15MG,20MG,30MG)

ARIPIPRAZOLE OTSUKA
2MG,5MG,10MG,15MG,20MG,30MG
Yes No
2027-Mar-02 Expired
2021-Dec-12 None
None No
ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: • Schizophrenia • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I • Adjunctive Treatment of Major Depressive Disorder • Irritability Associated with Autistic Disorder • Treatment of Tourette’s disorder.
17 3 13
Total Other Developers 7
Drugs with Suitability No
2MG ** ** - - 13
5MG ** ** - - 13
10MG ** ** - - 13
15MG ** ** - - 13
20MG ** ** - - 13
30MG ** ** - - 13
NDA Sales Available Total Generic Sales Available
Yes 13
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ******* ******* *************** ******* *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** **** **. */*** ** ***, ***** *** ****-**, ****** *****, ****. *******, *******, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** ***/*-***, ******* ****** **** ***** *********, *****, *********, ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** ****** **** *** * ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ****** ****** *** ****** ****** ******* *********** *-*\*\*, **** ****, *******, *********** *************, *********** ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***, ******* ****** ***** *****, *******, ******, *****, ***** & *** ******, ***** (***) ***
****** ****** ****** ****** ******* ******** ******** *** *********** *** ** ******* ***/***, ***********, *** ****** (**) *****-****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.